Kildjean (871084) writes "Late last week, we noted that Active Storage appeared set to introduce a replacement for Apple's Xserve, which is being discontinued as of today. The company followed through today with its introduction of ActiveSAN, a new metadata controller appliance to fill the void left by Xserve's departure. "On the day that Apple has formally stopped selling Xserve, we have exciting news. Until now, Apple's Xserve was the Metadata Controller of choice for most Xsan installations, providing enterprise form factor and capabilities," said Alex Grossman, CEO of Active Storage, Inc.
"Xsan users in high-pressure industries require datacenter-level quality products to manage their Metadata, but also demand the ease of use and setup of Xsan," continued Grossman. "Previously, that meant one thing: Xsan on an Xserve. But all that changes today — with ActiveSAN."
ActiveSAN is a 1U rackmountable controller based on Linux and the Quantum StorNext SAN file system. Active Storage also offers an integrated Mac OS X user interface to make setup and maintenance a fast and simple process.
ActiveSAN runs on a quad-core Xeon processor with 8 GB of 1066MHz DDR3 memory while offering mirrored hot-swappable 1 TB drives, a dual port 8Gb Fibre Channel card, and dual hot-swappable power supplies.
Full details on pricing and configuration options for ActiveSAN are yet to be announced, and Active Storage plans to demo the new hardware at NAB 2011 in early April with product availability set to follow soon after." Link to Original Source top
Kildjean (871084) writes "Engadget reports that Apple has issued invitations for a special media event to be held next Wednesday, October 20th at 10:00 AM Pacific Time. The invitation for the event, which is to be held at the company's campus in Cupertino, California, carries the tagline "Back to the Mac".
The invitation also contains an image of what appears to be a lion peeking out from behind the Apple logo, hinting at discussion of Mac OS X 10.7. "Lion" has been one of the most commonly-suggested "big cat" names for the next-generation operating system.
Much of Apple's notebook line with the exception of the entry-level MacBook is due for a refresh, and Apple has refreshed at least a portion of its notebook line each October or November for the last several years. Apple's desktop offerings have all been updated relatively recently, suggesting that the company's media event may focus on notebooks if new hardware is included on the agenda." Link to Original Source top
Gilbert Palau writes "I work in a large IT Service firm that administers IT NOC's for corporations in the eastern states (Md, DC, VA, NJ, etc). We have been looking for a enterprise size application for Remote Management and Image Deployment. The only one we have come accross that offers everything we want to do is Apple Remote Desktop. I have been searching in finding an application for Windows Server Environments and Networks with Windows XP Clients that has all the tools included in ARD, but I have only found it in separate products that one way or another fall short from the type of performance and tools we are looking. I specially can't believe that being part of the dominating OS species, I cannot find an application that does for Apple Networks, on the Windows Environment. We are looking for a tool where we can do Software Distribution, Asset Management, Remote Assistance, Remote Administration and scheduling of application deployment. I would appreciate if any IT engineers give me their input on what would be the best application to deploy for this type of work or which application compares or is better than apple remote desktop that is windows environment based." Link to Original Source top
Since the original publication of this article we have been inundated with responses from the public at all walks of life. It is important to note that research is ongoing with DCA, and not everyone is convinced it will turn out to be a miracle drug. There have been many therapies that were promising in vitro and in animal models that did not work for one reason or another in humans. To provide false hope is not our intention. There is a lot of information on DCA available on the web, and this column is but one opinion on the topic. We hope you will do your own research into the situation. So, we have added links to resources at the end of this column.
Scientists may have cured cancer last week.
So, why hven't the media picked up on it?
Here's the deal. Researchers at the University of Alberta in Edmonton, Canada found a cheap and easy to produce drug that kills almost all cancers. The drug is dichloroacetate, and since it is already used to treat metabolic disorders, we know it should be no problem to use it for other purposes.
Doesn't this sound like the kind of news you see on the front page of every paper?
The drug also has no patent, which means it could be produced for bargain basement prices in comparison to what drug companies research and develop.
Scientists tested DCA on human cells cultured outside the body where it killed lung, breast and brain cancer cells, but left healthy cells alone. Rats plump with tumors shrank when they were fed water supplemented with DCA.
Again, this seems like it should be at the top of the nightly news, right?
Cancer cells don't use the little power stations found in most human cells — the mitochondria. Instead, they use glycolysis, which is less effective and more wasteful.
Doctors have long believed the reason for this is because the mitochondria were damaged somehow. But, it turns out the mitochondria were just dormant, and DCA starts them back up again.
The side effect of this is it also reactivates a process called apoptosis. You see, mitochondria contain an all-too-important self-destruct button that can't be pressed in cancer cells. Without it, tumors grow larger as cells refuse to be extinguished. Fully functioning mitochondria, thanks to DCA, can once again die.
With glycolysis turned off, the body produces less lactic acid, so the bad tissue around cancer cells doesn't break down and seed new tumors.
Here's the big catch. Pharmaceutical companies probably won't invest in research into DCA because they won't profit from it. It's easy to make, unpatented and could be added to drinking water. Imagine, Gatorade with cancer control.
So, the groundwork will have to be done at universities and independently funded laboratories. But, how are they supposed to drum up support if the media aren't even talking about it?
All I can do is write this and hope Google News picks it up. In the meantime, tell everyone you know and do your own research.
This is a column of opinion written by Printz Executive Editor David McRaney. Comments can be sent to firstname.lastname@example.org
Kildjean writes ""Gizmodo Knows: iPhone Will Be Announced On Monday. I guarantee it. It isn't what I expected at all. And I've already said too much."
Read into that what you will. First thing I notice is the lack of the word "Apple," other than in the tags. Sure, an iPhone could be coming Monday — but is it the iPhone. The only true iPhone is one from Apple. You must forsake all others.
Or maybe they've actually got the goods this time? Tune in Monday to find out and discuss amongst yourselves in the interim."